HLS Shares Healius Limited
ASX · ASXLast in our picks 2026-10-21 — not in the current list; analysis below is from that screen
Healthcare services demand and restructuring provide potential turnaround upside, with elevated execution risk.
Future value: $0.55 (+40.87%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Turnaround restructuring is the primary near-term catalyst.
- ▾Below 50-day MA (-6.07%)
- ▾Near 52-week low (11.7% of range)
- ▸~41% upside to price target
Is HLS a buy right now?
Trend: HLS is trading above the 50-day average (+7.32%), RSI 20 — oversold territory, with a 3-month return of +20.55%.
Valuation & quality: Healius Limited trades on forward P/E 141.0, PEG 1.60, price-to-book 1.86; fundamentals show net margin -30.3%, return on equity -107.7%.
Analyst consensus: 10 analysts have a mean 12-month price target of A$0.55 (+25% vs the last close; range A$0.35 – A$1.30), consensus rating “hold”.
Our screen: ACCUMULATE (score 1) — Healthcare services demand and restructuring provide potential turnaround upside, with elevated execution risk.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -20.30% | -9.10% | -32.00% | +14.70% | -2.60% | +13.20% | +0.00% | +2.30% |
Fundamentals
Analyst price target
Technical signals
About Healius Limited
Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab…
Sector: Healthcare · Industry: Diagnostics & Research · Australia · 3,343 employees · Website
Related Consumer Staples picks
Browse: all ASX stocks · Consumer Staples picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.